These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma. Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917 [TBL] [Abstract][Full Text] [Related]
26. Reactive T cells by flow cytometry distinguish Hodgkin lymphomas from T cell/histiocyte-rich large B cell lymphoma. Wu D; Thomas A; Fromm JR Cytometry B Clin Cytom; 2016 Sep; 90(5):424-32. PubMed ID: 26084540 [TBL] [Abstract][Full Text] [Related]
27. Modern management of lymphocyte-predominant Hodgkin lymphoma. Xing KH; Savage KJ Br J Haematol; 2013 May; 161(3):316-29. PubMed ID: 23398605 [TBL] [Abstract][Full Text] [Related]
29. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base. Olszewski AJ; Shrestha R; Cook NM Cancer; 2015 Oct; 121(19):3472-80. PubMed ID: 26149294 [TBL] [Abstract][Full Text] [Related]
30. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Eichenauer DA; Engert A Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522 [TBL] [Abstract][Full Text] [Related]
31. Utility of fascin and JunB in distinguishing nodular lymphocyte predominant from classical lymphocyte-rich Hodgkin lymphoma. Bhargava P; Pantanowitz L; Pinkus GS; Pinkus JL; Paessler ME; Roullet M; Gautam S; Bagg A; Kadin ME Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):16-23. PubMed ID: 19550297 [TBL] [Abstract][Full Text] [Related]
32. Large B-cell lymphoma with T-cell-rich background and nodules lacking follicular dendritic cell meshworks: description of an insufficiently recognized variant. Treetipsatit J; Metcalf RA; Warnke RA; Natkunam Y Hum Pathol; 2015 Jan; 46(1):74-83. PubMed ID: 25456392 [TBL] [Abstract][Full Text] [Related]
33. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013 [TBL] [Abstract][Full Text] [Related]
34. Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment. Goel A; Fan W; Patel AA; Devabhaktuni M; Grossbard ML Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):261-70. PubMed ID: 24650975 [TBL] [Abstract][Full Text] [Related]
35. IgD positive L&H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma. Prakash S; Fountaine T; Raffeld M; Jaffe ES; Pittaluga S Am J Surg Pathol; 2006 May; 30(5):585-92. PubMed ID: 16699312 [TBL] [Abstract][Full Text] [Related]
36. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group. Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO; Leuk Lymphoma; 2003 Nov; 44(11):1903-10. PubMed ID: 14738141 [TBL] [Abstract][Full Text] [Related]
37. Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group. Shankar AG; Kirkwood AA; Depani S; Bianchi E; Hayward J; Ramsay AD; Hall GW Br J Haematol; 2016 May; 173(3):421-31. PubMed ID: 26996288 [TBL] [Abstract][Full Text] [Related]
38. Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options. Shankar A; Daw S Br J Haematol; 2012 Nov; 159(3):288-98. PubMed ID: 22994199 [TBL] [Abstract][Full Text] [Related]
39. Nodular lymphocyte-predominant Hodgkin lymphoma: cytopathologic correlates on fine-needle aspiration. Subhawong AP; Ali SZ; Tatsas AD Cancer Cytopathol; 2012 Aug; 120(4):254-60. PubMed ID: 22367911 [TBL] [Abstract][Full Text] [Related]